Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
UroGen Pharma Ltd is a biotechnology business based in the US. UroGen Pharma shares (URGN) are listed on the NASDAQ and all prices are listed in US Dollars. UroGen Pharma employs 190 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$16.95|
|52-week range||$14.19 - $28.20|
|50-day moving average||$15.86|
|200-day moving average||$17.32|
|Wall St. target price||$42.60|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-5.02|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-09-17)||1.62%|
|1 month (2021-08-26)||11.44%|
|3 months (2021-06-25)||0.06%|
|6 months (2021-03-26)||-13.17%|
|1 year (2020-09-25)||-12.22%|
|2 years (2019-09-26)||-32.44%|
|3 years (2018-09-26)||48.83|
|5 years (2016-09-22)||N/A|
|Revenue TTM||$31.9 million|
|Gross profit TTM||$10.8 million|
|Return on assets TTM||-41.81%|
|Return on equity TTM||-112.1%|
|Market capitalisation||$373 million|
TTM: trailing 12 months
There are currently 2.2 million UroGen Pharma shares held short by investors – that's known as UroGen Pharma's "short interest". This figure is 0.5% down from 2.2 million last month.
There are a few different ways that this level of interest in shorting UroGen Pharma shares can be evaluated.
UroGen Pharma's "short interest ratio" (SIR) is the quantity of UroGen Pharma shares currently shorted divided by the average quantity of UroGen Pharma shares traded daily (recently around 120156.11080934). UroGen Pharma's SIR currently stands at 18.41. In other words for every 100,000 UroGen Pharma shares traded daily on the market, roughly 18410 shares are currently held short.
However UroGen Pharma's short interest can also be evaluated against the total number of UroGen Pharma shares, or, against the total number of tradable UroGen Pharma shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case UroGen Pharma's short interest could be expressed as 0.1% of the outstanding shares (for every 100,000 UroGen Pharma shares in existence, roughly 100 shares are currently held short) or 0.1175% of the tradable shares (for every 100,000 tradable UroGen Pharma shares, roughly 118 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against UroGen Pharma.
Find out more about how you can short UroGen Pharma stock.
We're not expecting UroGen Pharma to pay a dividend over the next 12 months.
Over the last 12 months, UroGen Pharma's shares have ranged in value from as little as $14.19 up to $28.2. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while UroGen Pharma's is 1.2061. This would suggest that UroGen Pharma's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
UroGen Pharma Ltd. , a biopharmaceutical company, engages in the development and commercialization novel solutions for specialty cancers and urologic diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-302 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer.
Everything we know about the Enfusion IPO, plus information on how to buy in.
Everything we know about the Intuity Medical IPO, plus information on how to buy in.
Everything we know about the Pyxis Oncology IPO, plus information on how to buy in.
Everything we know about the AEON Biopharma IPO, plus information on how to buy in.
Everything we know about the IHS Holding Ltd IPO, plus information on how to buy in.
Everything we know about the BT Brands IPO, plus information on how to buy in.
Everything we know about the Immix IPO, plus information on how to buy in.
Everything we know about the Keter Group SA IPO, plus information on how to buy in.
Everything we know about the Theseus Pharmaceuticals IPO, plus information on how to buy in.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq on Sep. 20, 2021
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.